First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly.

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas

GATTO, FEDERICO;FERONE, DIEGO;
2017-01-01

Abstract

First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly.
File in questo prodotto:
File Dimensione Formato  
In Vitro Head-to-Head Comparison Between Octreotide.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 863.21 kB
Formato Adobe PDF
863.21 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/869853
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 47
social impact